Clinical Outcome of Stereotactic Ablative Body Radiotherapy for Lung Metastatic Lesions in Non-small Cell Lung Cancer Oligometastatic Patients

Clinical Oncology

Volumn 28, Issue 1, 2016, Pages 13-20

  De Rose, F ^a   Cozzi, L ^a   Navarria, P ^a   Ascolese, A M ^a   Clerici, E ^a   Infante, M ^a   Alloisio, M ^a   Testori, A ^a   Toschi, L ^a   Finocchiaro, G ^a   Santoro, A ^a   Scorsetti, M ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Metastases; NSCLC; Oligometastatic disease; SABR; Volumetric modulated arc therapy

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER PATIENT; CANCER SIZE; FEMALE; HUMAN; LINEAR ACCELERATOR; LOCAL THERAPY; LUNG METASTASIS; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE; ADVERSE EFFECTS; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM METASTASIS; PATHOLOGY; PROCEDURES; RADIOSURGERY; SECONDARY;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RADIOSURGERY; TREATMENT OUTCOME;

EID: 84941687283     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2015.08.011     Document Type: Article

References (44)

1. Jemal A., Bray F., Center M., et al. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Walters S., Maringe C., Coleman M., et al. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004-2007. Thorax 2013, 68:551-564.
3. Peters S., Adjei A., Gridelli C., et al. Metastatic non-small cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012, 23:56-64.
4. Mok T. Personalized medicine in lung cancer: what we need to know. Nat Rev Clin Oncol 2011, 8:661-668.
5. Niibe Y., Chang J. Novel insights of oligometastases and oligo-recurrence and review of the literature. Pulm Med 2012, 2012:261096.
6. Hellman S., Weichselbaum R. Oligometastases. J Clin Oncol 1995, 13:8-10.
7. Griffioena G., Togurib D., Dahelea M., et al. Radical treatment of synchronous oligometastatic non-small cell lungcarcinoma (NSCLC): patient outcomes and prognostic factors. Lung Cancer 2013, 82:95-102.
8. Pastorino U., Buyse M., Friedel G., et al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg 1997, 113:37-47.
9. Pfannschmidt J., Dienemann H., Hoffmann H. Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series. Ann Thorac Surg 2007, 84:324-338.
10. Treasure T. Pulmonary metastasectomy: a common practice based on weak evidence. Ann R Coll Surg Engl 2007, 89:744-748.
11. Hornbech K., Ravn J., Steinbruchel D. Current status of pulmonary metastasectomy. Eur J Cardiothorac Surg 2011, 39:955-962.
12. Pulmonary Metastasectomy in Colorectal Cancer (PulMICC) Trial. UK Clinical Research Network: Portfolio Database. Available at:. http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=9018.
13. Brock J., Ashley S., Bedford J., Nioutsikou E., Partridge M., Brada M. Review of hypofractionated small volume radiotherapy for early stage non small cell lung cancer. Clin Oncol 2008, 20:666-676.
14. Palma D., Visser O., Lagerwaard F., et al. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non small-cell lung cancer: a population-based time-trend analysis. J Clin Oncol 2010, 28:5153-5159.
15. Baumann P., Nyman J., Hoyer M., et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 2009, 27:3290-3296.
16. Onishi H., Shirato H., Nagata Y., et al. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery?. Int J Radiat Oncol Biol Phys 2011, 81:1352-1358.
17. Rusthoven K., Kavanagh B., Burri S., et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol 2009, 27:1579-1584.
18. Navarria P., Ascolese M., Tomatis S., et al. Stereotactic body radiotherapy (SBRT) in lung oligometastatic patients: role of local treatments. Radiat Oncol 2014, 9:91.
19. Navarria P., Ascolese A., Cozzi L., et al. Stereotactic body radiation therapy for lung metastases from soft tissue sarcoma. Eur J Cancer 2015, 51:668-674.
20. Filippi A., Badellino S., Guarneri A., et al. Outcomes of single fraction stereotactic ablative radiotherapy for lung metastases. Technol Cancer Res Treat 2014, 13:37-45.
21. Hanna G., Landau D. Stereotactic body radiotherapy for oligometastatic disease. Clin Oncol 2015, 27:290-297.
22. Timmerman R., McGarry R., Yiannoutsos C., et al. Excessive toxicity when treating central tumours in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006, 24:4833-4839.
23. Kong F., Ritter T., Quint D., et al. Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus. Int J Radiat Oncol Biol Phys 2011, 81:1442-1457.
24. Eisenhauer E., Therasse P., Bogaerts J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
25. Huang K., Dahele M., Senan S., et al. Radiographic changes after lung stereotactic ablative radiotherapy (SABR) - can we distinguish recurrence from fibrosis? A systematic review of the literature. Radiother Oncol 2012, 102:335-342.
26. Villaruz L., Kubicek G., Socinski M. Management of non-small cell lung cancer with oligometastasis. Curr Oncol Rep 2012, 14:333-341.
27. Lo S., Sahgal A., Chang E., et al. Serious complications associated with stereotactic ablative radiotherapy and strategies to mitigate the risk. Clin Oncol 2013, 25:378-387.
28. Fritz P., Kraus H., Muhlnickel W., et al. Stereotactic, single-dose irradiation of stage I non-small cell lung cancer and lung metastases. Radiat Oncol 2006, 1:30.
29. Hof H., Hoess A., Oetzel D., et al. Stereotactic single-dose radiotherapy of lung metastases. Strahlenther Onkol 2007, 183:673-678.
30. Osti M., Carnevale A., Valeriani M., et al. Clinical outcomes of single dose stereotactic radiotherapy for lung metastases. Clin Lung Canc 2013, 14:699-703.
31. Norihisa Y., Nagata Y., Takayama K., et al. Stereotactic body radiotherapy for oligometastatic lung tumours. Int J Radiat Oncol Biol Phys 2008, 72:398-403.
32. Milano M., Katz A., Muhs A., et al. A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions. Cancer 2008, 112:650-658.
33. Inoue T., Oh R., Shiomi H., et al. Stereotactic body radiotherapy for pulmonary metastases. Prognostic factors and adverse respiratory events. Strahlenther Onkol 2013, 189:285-292.
34. Ricardi U., Filippi A., Guarneri A., et al. Stereotactic body radiation therapy for lung metastases. Lung Cancer 2012, 75:77-81.
35. Salama J., Hasselle M., Chmura S., et al. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer 2011, 118:2962-2970.
36. Wersäll P., Blomgren H., Lax I., et al. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother Oncol 2005, 77:88-95.
37. Thibault I., Poon I., Yeung L., et al. Predictive factors for local control in primary and metastatic lung tumours after four to five fraction stereotactic ablatice body radiotherapy. A single institution's comprehensive experience. Clin Oncol 2014, 25:713-719.
38. Ashworth A., Senan S., Palma D., et al. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic nonesmall-cell lung cancer. Clin Lung Cancer 2014, 15:346-355.
39. Mercier O., Fadel E., de Perrot M., et al. Surgical treatment of solitary adrenal metastasis from non small-cell lung cancer. J Thorac Cardiovasc Surg 2005, 130:136-140.
40. Porte H., Siat J., Guibert B., et al. Resection of adrenal metastases from none small-cell lung cancer: a multicenter study. Ann Thorac Surg 2001, 71:981-985.
41. Salah S., Tanvetyanon T., Abbasi S. Metastatectomy for extra-cranial extra-adrenal non-small-cell lung cancer solitary metastases: systematic review and analysis of reported cases. Lung Cancer 2012, 75:9-14.
42. Raz D., Lanuti M., Gaissert H., et al. Outcomes of patients with isolated adrenal metastasis from nonesmall-cell lung carcinoma. Ann Thorac Surg 2011, 92:1788-1792.
43. Rami-Porta R., Crowley J., Goldstraw P. The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg 2009, 15:4-9.
44. Iyengar P., Kavanagh B., Wardak Z., et al. Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. J Clin Oncol 2014, 32:3824-3830.